Quintiles Receives Technology Security Award from IDG’s CSO Magazine for Fourth Consecutive Year
Quintiles, the world’s leading provider of biopharmaceutical services , announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine . This award recognizes the company’s innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company’s fourth consecutive year receiving the prestigious security award.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160422005063/en/
Quintiles’ Identity Management Solution introduced identity vetting, identity storage and identity synchronization that improved data quality for both existing and newly established users. The resulting system supports faster business enablement of critical project activities including site start-up while reducing identity-based security risks.
“As a company operating in over 100 countries and executing trials with over 38,000 partner investigators globally, we recognized the need for a global, simplified solution,” said Charles Newberry, chief information security officer at Quintiles. “As more clinical development activities accelerate toward digital solutions, secure user access to systems and data that improve speed and accuracy are even more critical. The Identity Management Solution is designed with those trends in mind — simultaneously reducing administrative burden and expediting crucial clinical trial activities while maintaining the integrity and security of users’ data.”
Each year, the CSO50 Awards recognize 50 organizations for security projects and initiatives that demonstrate outstanding business value and thought leadership. Nominations are scored on a uniform set of criteria by a panel of judges including security leaders, industry experts, and academics. The final winning selections are made by CSO's editors based on this scoring process.
“We are honored to receive this award which reflects our world-class security team and software development teams who pioneered this innovative approach,” Newberry added.
“Security professionals know that securing an organization is about much more than mere defense today; it’s also about enabling business and driving ROI,” said Joan Goodchild, editor in chief, CSO. “Our annual CSO50 Awards recognize the innovation, creativity and business acumen that goes into creating outstanding security projects. We congratulate each of our winners for their accomplishments in creating projects that not only demonstrate state-of-the-art security, but exemplary business value as well.”
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the Fortune 500 and has been named to Fortune’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com .
Click here to subscribe to Mobile Alerts for Quintiles.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
OCTAPHARMA18.6.2018 09:08 | pressemeddelelse
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A
IL-STATS18.6.2018 09:02 | pressemeddelelse
STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup
CELLTRION18.6.2018 04:55 | pressemeddelelse
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar
CTA15.6.2018 17:01 | pressemeddelelse
CES Asia: Innovation at the Speed of 5G
MA-BLUEBIRD-BIO15.6.2018 12:02 | pressemeddelelse
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association
MA-BLUEBIRD-BIO15.6.2018 12:02 | pressemeddelelse
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum